CORE COMPETENCIES

What we do

The focus of our site is on the reliable production of high-quality medicinal products. This is guaranteed on the one hand by our range of reliable active ingredients, and on the other hand by our modern machinery with extensive automation functions of the latest generation. For example, a new pharmaceutical mixer, a coater, a fluid bed granulator and a high-speed blister line were installed between 2018 and 2021 to improve the performance and capacity of the plant.

Of the approximately ten active substances processed by us, the proton pump inhibitor Pantoprazole takes the top position with approx. 700 to 800 million tablets per year. This makes us one of the largest manufacturers of Pantoprazole medicines in Europe. Other top products are various statins, citalopram and carbamazepine. 

In addition to prescription medicines, OTC preparations complete our range: Well-known medicines sold under the Aristo Pharma brand are Sedariston® capsules, Solidago Steiner® and Sogoon®.

Tablets

We have modern facilities for the production of tablets and their proper packaging into blisters. The heart of our tablet production is the ultra-modern high-speed blister line, which packs all common tablet formats at a speed of up to 700 blisters per minute.

We produce an average of two billion tablets per year – at full capacity our production reaches quantities of over three billion. After compression, the active ingredients and excipients are usually coated with a coating film before being packed in blisters and folding boxes. Filming the finished tablet formulations gives the active ingredients a protective layer to minimise the influence of light, air and oxidation. A coloured film also helps to distinguish between different tablets.

We also offer the possibility of coating tablets. Dragees are considered the precursor of film-coated tablets: they are coated with a layer of sugar, which covers up any unpleasant taste or smell of the tablet core.

Capsules

Due to their galenics, the administration of certain formulations in capsule rather than tablet form is necessary. Currently, we produce two medicinal products on our proven production line that are administered as hard gelatine capsules. We have a capacity of about 200 to 300 million capsules per year.

Although the production of hard capsules is more demanding and cost-intensive compared to tablet production, it does have some advantages. For example, the sensitive active ingredient is better protected from external influences such as light.

Our quality standards

We ensure that all quality requirements and industry-typical standards are met through regular inspections. This begins as soon as the raw materials arrive at the warehouse, where we draw samples and examine them in the laboratory. 

As a company that follows the guidelines of Good Manufacturing Practice (GMP), we guarantee, for example, the effectiveness and safety of the active substances used and a hygienically impeccable environment. We also have a broad knowledge of cleaning validation. 

In addition, we undergo regular inspections by the authorities and grant our customers access to our production processes in recurring audits.

Laboratory analyses

In addition to carrying out routine and industry-standard quality tests, we also develop new analytical methods and conduct stability tests for our third-party customers. Recipe adaptations and improvements, scale-up trials and technical transfers are also part of our product portfolio. 

This allows us to offer the complete portfolio of a modern pharmaceutical company in the laboratory area.

Pharmaceutical storage

Storage and logistics play a central role in reliable supply chain management. To meet the high demand for raw materials for our production, we have storage capacity for 4,000 tonnes of bulk solids.